Sanara MedTech Returns to Profitability with Strong Q1 Revenue Growth

summarizeSummary

Sanara MedTech Inc. reported a return to net profitability in Q1 2026, driven by 19% revenue growth in its core surgical business and the successful discontinuation of its loss-making THP segment.

check_boxKey Events

• Return to Net Profitability

  The company achieved net income from continuing operations of $0.4 million in Q1 2026, a significant improvement from a net loss of $0.6 million in Q1 2025. Net income attributable to shareholders was $0.46 million, compared to a $3.53 million loss in the prior year.

• Strong Revenue Growth

  Net revenue increased by 19% to $27.8 million in Q1 2026, up from $23.4 million in Q1 2025, primarily driven by increased sales of soft tissue repair products like CellerateRX Surgical and BIASURGE.

• Adjusted EBITDA Surges

  Adjusted EBITDA grew by 58% to $4.3 million in Q1 2026, compared to $2.7 million in Q1 2025, reflecting improved operational performance.

• Strategic Shift Validated

  The wind-down of the loss-making Tissue Health Plus (THP) segment is substantially complete, and related earnout liabilities for the CarePICS Acquisition and Applied Asset Purchase have been reduced to zero, removing future financial obligations and focusing the company on its profitable surgical market.

auto_awesomeAnalysis

Sanara MedTech Inc. reported a significant financial turnaround in Q1 2026, achieving net income from continuing operations of $0.4 million, a substantial improvement from a $0.6 million net loss in the prior year. This positive shift is driven by robust 19% revenue growth in its continuing surgical operations and a 58% increase in Adjusted EBITDA. The company has also successfully wound down its loss-making Tissue Health Plus (THP) segment, eliminating associated earnout liabilities and streamlining its focus on the profitable surgical market. This report validates the company's strategic realignment and demonstrates improved financial health and operational efficiency.